Potential efficacy of dopamine loaded‐PVP/PAA nanogel in experimental models of Parkinsonism: Possible disease modifying activity
Source abstract
Abstract
Abstract This study aimed to investigate the ability of dopamine (DA)‐loaded polyvinylpyrrolidone‐poly(acrylic acid) (PVP/PAAc) nanogel [synthesized by gamma (γ) radiation‐induced template polymerization] [Nano‐DA] to deliver DA across the blood brain barrier, and to evaluate the efficacy and safety of the acute and subchronic administration of Nano‐DA in modulating motor activity and/or the biochemical changes in rat brain; induced by different models of Parkinsonism. In this respect, (PVP/PAAc) nanogel was synthesized by gamma radiation‐induced polymerization of acrylic acid (AAc) in an aqueous solution of PVP as a template polymer, and then, it was used as a nano‐drug carrier for DA. The PVP/PAAc and (PVP/PAAc loaded‐DA nanogel particles were characterized by dynamic light scattering, infrared spectroscopy, and field emission‐scanning electron microscopy. The loaded gel was administered in different doses and dosing regimens to Parkinsonian rats, and the catalepsy score and striatal DA levels were assessed. Then, the potential disease‐modifying activity of this form of DA was investigated, through the assessment of the improvement in mitochondrial function, following the subchronic administration of Nano‐DA to Parkinsonian rats. Significant disease‐modifying effects were observed upon the administration of Nano‐DA; in addition to normalization in their motor activity. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 103A: 1713–1720, 2015.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Parkinson's Disease Mechanisms and Treatments · Ginkgo biloba and Cashew Applications · Neurological disorders and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Drug Radiation Research National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority Nasr City Cairo Egypt
Department of Polymers National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority Nasr City Cairo Egypt
References (44)
Show source-provided references
1. 10.1007/3-540-69682-2_410.1007/3-540-69682-2_4 ↗
2. 10.1016/j.progpolymsci.2011.01.00110.1016/j.progpolymsci.2011.01.001 ↗
3. 10.1021/ma981945s10.1021/ma981945s ↗
4. 10.1016/j.radphyschem.2014.04.01610.1016/j.radphyschem.2014.04.016 ↗
5. Ulanski P · 2004 · 845
6. 10.1161/01.CIR.11.2.17010.1161/01.CIR.11.2.170 ↗
7. 10.1016/j.neuroscience.2007.04.00210.1016/j.neuroscience.2007.04.002 ↗
8. El‐GhazalyMA SadikNA RashedER Abd El‐FattahAA. Neuroprotective effect of EGb761® and low‐dose whole‐body gamma‐irradiation in a rat model of Parkinson's disease. Toxicol Ind Health. Online 21 May 2013.10.1177/0748233713487251 ↗
9. 10.1038/8183410.1038/81834 ↗
10. 10.1016/j.nbd.2009.01.01610.1016/j.nbd.2009.01.016 ↗
11. 10.1172/JCI2917810.1172/JCI29178 ↗
12. 10.1016/j.neuropharm.2008.08.03310.1016/j.neuropharm.2008.08.033 ↗
13. 10.1001/jama.291.3.35810.1001/jama.291.3.358 ↗
14. 10.1038/sj.cr.729023510.1038/sj.cr.7290235 ↗
15. 10.1080/0265204001001811910.1080/02652040010018119 ↗
16. 10.1016/j.ijpharm.2009.08.02110.1016/j.ijpharm.2009.08.021 ↗
17. Preparation and in‐vitro evaluation of indomethacin nanoparticles
18. 10.2217/17435889.2.6.78910.2217/17435889.2.6.789 ↗
19. 10.1016/j.eurpolymj.2012.12.00210.1016/j.eurpolymj.2012.12.002 ↗
20. 10.2116/analsci.25.145110.2116/analsci.25.1451 ↗
21. 10.1016/S0306-4522(96)00407-110.1016/S0306-4522(96)00407-1 ↗
22. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease10.1096/fj.14.10.1432 ↗
23. 10.1016/S0006-8993(00)02960-710.1016/S0006-8993(00)02960-7 ↗
24. 10.1016/j.bbr.2003.12.02110.1016/j.bbr.2003.12.021 ↗
25. 10.1016/S0531-5565(00)00181-910.1016/S0531-5565(00)00181-9 ↗
26. Chu EH Hamster cell mutants unable to grow on galactose and exhibiting an overlapping complementation pattern are defective in the electron transport chain10.1016/S0021-9258(19)69040-X ↗
27. 10.1006/jmcc.1994.100610.1006/jmcc.1994.1006 ↗
28. 10.1016/S0021-9258(19)52451-610.1016/S0021-9258(19)52451-6 ↗
29. Improved method for the determination of blood glutathione
30. 10.1016/0003-2697(78)90342-110.1016/0003-2697(78)90342-1 ↗
31. 10.1016/S0099-5428(08)60172-010.1016/S0099-5428(08)60172-0 ↗
32. 10.1016/j.apt.2013.04.00610.1016/j.apt.2013.04.006 ↗
33. 10.1021/bm301742m10.1021/bm301742m ↗
34. 10.1021/ma061713q10.1021/ma061713q ↗
35. 10.1021/cm070042n10.1021/cm070042n ↗
36. 10.1016/S0091-3057(02)01051-110.1016/S0091-3057(02)01051-1 ↗
37. 10.1523/JNEUROSCI.23-34-10756.200310.1523/JNEUROSCI.23-34-10756.2003 ↗
38. 10.1007/978-3-211-45295-0_4210.1007/978-3-211-45295-0_42 ↗
39. 10.1111/j.1749-6632.2003.tb07469.x10.1111/j.1749-6632.2003.tb07469.x ↗
40. 10.1074/jbc.M21043220010.1074/jbc.M210432200 ↗
41. 10.1016/j.ijbiomac.2013.10.00410.1016/j.ijbiomac.2013.10.004 ↗
42. 10.1016/j.drudis.2011.02.00610.1016/j.drudis.2011.02.006 ↗
43. 10.4236/eng.2012.410B00710.4236/eng.2012.410B007 ↗
44. 10.1016/j.ijpharm.2011.07.03610.1016/j.ijpharm.2011.07.036 ↗